NCT06671691Enrolling by invitationPhase 1
A Phase I Dose-escalation Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Low-risk Breast Cancer Patients: DESERT I Trial
Phase I Dose-Escalation Clinical Trial of Definitive Single Dose Stereotactic Body Radiotherapy in Patients with Low-risk Hormone Receptor-positive and Her2-negative Breast Cancer Not Suitable or Who Refuse Surgery: DESERT I Trial
Source: ClinicalTrials.gov · Last updated 4 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Radiotherapy (RT) is a fundamental pillar in the fight against cancer. In the case of breast cancer, RT has traditionally been applied as an adjuvant treatment following surgery. However, in recent years, there has been research into the potential benefit of administering RT prior to surgery in a neoadjuvant manner. Given that these studies have shown promising results, it is logical to think that certain patients could benefit from exclusive RT treatment, thereby avoiding surgery and its possible sequelae. This study is a phase I dose-escalation clinical trial with sequential assignment, open-label, in which five different doses (20Gy, 23Gy, 26Gy, 28Gy, and 30Gy) will be tested on the tumor using stereotactic body radiotherapy (SBRT) technique. The aim of the study is to determine the maximum tolerated dose (MTD) based on acute toxicity, which will allow us to proceed with a phase II clinical trial to confirm efficacy and assess the late toxicity of the treatment. Secondary objectives include assessing the pathological response via core needle biopsy (CNB), radiological response, quality of life, and cosmesis. Additionally, molecular studies will be conducted on tissue and through liquid biopsy; pre- and post-treatment, we aim to identify mutations and predictors of response.
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 28 Oct 2024
- Start date
- 27 Sept 2024
- Primary completion date
- Sept 2025
- Lead sponsor
- Universitat de les Illes Balears
- Diseases
- Childhood cancers
- NCT number
- NCT06671691
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- From 27 Sept 2024 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of previous breast cancer in the same breast
- Previous thoracic radiotherapy
- Patient with breast implants
Other illness
- Patients with metastatic disease
- Scleroderma, lupus, or other connective tissue diseases with active flares
Age
- Under 18 years of age
Other
- Male gender
- ECOG score 3-4
- Positive biopsy for invasive lobular carcinoma or ductal carcinoma in situ
- Tumor ≥ 3 cm in diameter as measured by MRI
- Tumor located \< 0.5 cm from the skin or rib cage, clinically or radiologically
- Negative estrogen and progesterone receptors
- HER2 positive
- Presence of lymphovascular invasion in the biopsy
- Positive BRCA mutation
- Multicentric tumor
- Tumor with positive axillary lymph nodes
- Pregnant or actively breastfeeding
- Unable to undergo MRI or contrast mammography
- Unable to tolerate the supine position
- Patients with pacemakers
- Inability to understand and sign the informed consent
Who the study is looking for
- Over 18 years of age
- Female gender
- ECOG score 0-2
- Positive biopsy for invasive non-lobular breast tumor histology
- Tumor \< 3 cm in diameter as measured by MRI or contrast mammography
- Tumor located ≥ 0.5 cm from the skin or rib cage, clinically or radiologically
- Positive estrogen and/or progesterone receptors
- HER2 negative
- No lymphovascular invasion in the biopsy
- Tumor must be clinically and radiologically N0 (no lymph node involvement). If a suspicious lymph node is seen, it must be biopsied and show a negative result
- Patient weight below 220 kg (weight limit for the treatment table)
- Ability to tolerate the supine position for 20 minutes during treatment
- Able to undergo MRI and/or contrast mammography
- Not pregnant; women of childbearing potential will undergo a pregnancy test to rule this out
- Contraindication to or refusal of surgical treatment, which must be explicitly documented in the medical record.
Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario Son Espases Coordinator of this site? Confirm its status | Palma | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.